Avalo Therapeutics, Inc. (AVTX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 9M 18M 27M Q3 '16: 321.5K Q4 '16: 181K Q1 '17: 384 Q2 '17: 157.8K Q3 '17: 25M Q4 '17: 2.2M Q1 '18: 4.5M Q2 '18: 4.8M Q3 '18: 4.1M Q1 '19: 2.6M Q2 '19: 1.4M Q3 '19: 2.2M Q4 '19: 580.8K Q1 '20: 2.8M Q2 '20: 1.3M Q3 '20: 1.1M Q4 '20: 1.5M Q1 '21: 473K Q2 '21: 3.4M Q3 '21: 1.4M Q4 '21: 219K Q1 '22: 1.2M Q2 '22: 1M Q3 '22: 14.9M Q4 '22: 896K Q1 '23: 475K Q2 '23: 643K Q3 '23: 236K Q4 '23: 571K Q1 '24: 0 Q2 '24: 0 Q3 '24: 249K Q4 '24: 192K Q3 '25: 0 Q4 '25: 59K Q3 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '24 Q4 '25

Gross Profit Quarterly

-9M 0 9M 18M 27M Q1 '17: 384 Q2 '17: 157.8K Q3 '17: 25M Q4 '17: 1.6M Q1 '18: 3.6M Q2 '18: 3.4M Q3 '18: 963.5K Q1 '19: 1.8M Q2 '19: -104.7K Q3 '19: 2.1M Q4 '19: 535.6K Q1 '20: 2.7M Q2 '20: 1.3M Q3 '20: 1M Q4 '20: 1.4M Q1 '21: 396K Q2 '21: 3.3M Q3 '21: 442K Q4 '21: -205K Q1 '22: 453K Q2 '22: -534K Q3 '22: 14.4M Q4 '22: 276K Q1 '23: -76K Q2 '23: -65K Q3 '23: -11K Q1 '24: -80K Q2 '24: -343K Q3 '24: -465K Q1 '17 Q1 '18 Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q3 '24

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '16: -6M Q4 '16: -1.7M Q1 '17: -1.9M Q2 '17: -1.8M Q3 '17: 21.9M Q4 '17: -4.4M Q1 '18: -3.8M Q2 '18: -5.8M Q3 '18: -24.3M Q4 '18: -1.6M Q1 '19: -5M Q2 '19: -2.5M Q3 '19: -2.9M Q4 '19: -5.7M Q1 '20: -31.4M Q2 '20: -11.8M Q3 '20: -13.3M Q4 '20: -16.3M Q1 '21: -30.6M Q2 '21: -17.1M Q3 '21: -16.5M Q4 '21: -18M Q1 '22: -20.9M Q2 '22: -11.8M Q3 '22: 4.1M Q4 '22: -8.9M Q1 '23: -8.8M Q2 '23: -7.2M Q3 '23: -3.8M Q4 '23: -7.7M Q1 '24: -32.8M Q2 '24: -9.6M Q3 '24: -12.9M Q4 '24: -13.3M Q1 '25: -14.7M Q2 '25: -19.3M Q3 '25: -19.2M Q4 '25: -19.7M Q1 '26: -20.9M Q2 '26: -31.5M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '16: -6.2M Q4 '16: -1.6M Q1 '17: -2M Q2 '17: -1.8M Q3 '17: 18.7M Q4 '17: -3.1M Q1 '18: -3.9M Q2 '18: -6M Q3 '18: -24.6M Q4 '18: -5.6M Q1 '19: -7.5M Q2 '19: -6.2M Q3 '19: -4M Q4 '19: 1.6M Q1 '20: -21.1M Q2 '20: -13.3M Q3 '20: -13.5M Q4 '20: -15.6M Q1 '21: -30.7M Q2 '21: -17.1M Q3 '21: -17.4M Q4 '21: -19.2M Q1 '22: -22.1M Q2 '22: -13M Q3 '22: 3.2M Q4 '22: -9.8M Q1 '23: -10M Q2 '23: -8.2M Q3 '23: -5.2M Q4 '23: -8.2M Q1 '24: -121.3M Q2 '24: 98.5M Q3 '24: 23M Q4 '24: -35.3M Q1 '25: -13.1M Q2 '25: -20.8M Q3 '25: -30.6M Q4 '25: -13.7M Q1 '26: -19.6M Q2 '26: -36.4M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

-1.5M 0 1.5M 3M 4.5M Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 635.6K Q1 '18: 863.6K Q2 '18: 1.4M Q3 '18: 3.1M Q1 '19: 752.5K Q2 '19: -1.5M Q3 '19: 132.4K Q4 '19: 45.2K Q1 '20: 66K Q2 '20: 78K Q3 '20: 77K Q4 '20: 79K Q1 '21: 77K Q2 '21: 83K Q3 '21: 908K Q4 '21: 424K Q1 '22: 720K Q2 '22: 1.6M Q3 '22: 528K Q4 '22: 620K Q1 '23: 551K Q2 '23: 708K Q3 '23: 247K Q1 '24: -80K Q2 '24: 343K Q3 '24: -714K Q2 '25: 0 Q2 '17 Q2 '18 Q3 '19 Q3 '20 Q3 '21 Q3 '22 Q3 '23 Q2 '25

Operating Cash Flow Quarterly

-21M -14M -7M 0 7M 14M 21M Q3 '16: -3.4M Q4 '16: -3.7M Q1 '17: -2.2M Q2 '17: -1.8M Q3 '17: 19.1M Q4 '17: -2.5M Q1 '18: -280.4K Q2 '18: -333.7K Q3 '18: -538.4K Q4 '18: -2M Q1 '19: -3.1M Q2 '19: -6.7M Q3 '19: -7.6M Q4 '19: -1.7M Q1 '20: -5.7M Q2 '20: -8.6M Q3 '20: -11.9M Q4 '20: -14.4M Q1 '21: -18.3M Q2 '21: -19.2M Q3 '21: -16.3M Q4 '21: -17.1M Q1 '22: -16.1M Q2 '22: -12.5M Q3 '22: 5.7M Q4 '22: -3.9M Q1 '23: -10.1M Q2 '23: -11M Q3 '23: -6.8M Q4 '23: -2.8M Q1 '24: -6.2M Q2 '24: -16.3M Q3 '24: -11.5M Q4 '24: -15M Q1 '25: -9.5M Q2 '25: -11.4M Q3 '25: -16.4M Q4 '25: -14.2M Q1 '26: -17.7M Q2 '26: -20M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-21M -14M -7M 0 7M 14M 21M Q4 '14: -4M Q4 '15: -3.5M Q1 '16: -3.7M Q2 '16: -3.7M Q3 '16: -3.4M Q4 '16: -3.7M Q1 '17: -2.2M Q2 '17: -1.8M Q3 '17: 19.1M Q4 '17: -2.6M Q1 '18: -299.6K Q2 '18: -340.4K Q3 '18: -577.5K Q4 '18: -2.5M Q1 '19: -3.3M Q2 '19: -6.8M Q3 '19: -7.6M Q4 '19: -1.7M Q1 '20: -5.7M Q2 '20: -8.6M Q3 '20: -11.9M Q4 '20: -14.4M Q1 '21: -18.3M Q2 '21: -19.2M Q3 '21: -16.4M Q4 '21: -17.1M Q1 '22: -16.1M Q2 '22: -12.5M Q3 '22: 5.7M Q4 '22: -3.9M Q3 '23: -6.8M Q4 '23: -2.8M Q2 '16 Q2 '17 Q2 '18 Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q4 '23

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q3 '16: 8.8M Q3 '17: 21.4M Q3 '18: 34.6M Q1 '22: 9.4M Q2 '22: 9.4M Q3 '22: 9.4M Q1 '23: 48.8K Q2 '23: 58.2K Q3 '23: 194.9K Q1 '24: 859.4K Q2 '24: 7.7M Q3 '24: 10.8M Q1 '25: 10.5M Q2 '25: 10.8M Q3 '25: 14M Q1 '26: 20.1M Q2 '26: 43.6M Q3 '17 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1500.00 -1000.00 -500.00 0.00 500.00 1000.00 1500.00 Q4 '14: -25.01 Q1 '15: -24.28 Q2 '15: -22.37 Q3 '15: -14.40 Q4 '15: -11.05 Q1 '16: -6.66 Q2 '16: -2.59 Q3 '16: -2.23 Q4 '16: -1.86 Q1 '17: -1.46 Q2 '17: -1.19 Q3 '17: 0.03 Q4 '17: 0.08 Q1 '18: 0.15 Q2 '18: 0.10 Q3 '18: -1.13 Q4 '18: -1.17 Q4 '22: -1063.00 Q1 '23: -1264.65 Q2 '23: -1404.00 Q3 '23: -1431.17 Q4 '23: -113.58 Q1 '24: -50.72 Q2 '24: 75.94 Q3 '24: 99.94 Q4 '25: -5.73 Q1 '26: -5.46 Q2 '26: -4.37 Q3 '15 Q3 '16 Q3 '17 Q3 '18 Q2 '23 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.